(Nasdaq:ADMP) Adamis Pharmaceuticals Corp Hits 52 Week Low

Adamis Pharmaceuticals Corp (Nasdaq:ADMP)

August 21st, 2018

With markets going up Adamis Pharmaceuticals Corp finished Monday’s trading session down 4.08%, a $0.10 decrease to close on $2.35. As well as the drop in value, Adamis Pharmaceuticals Corp hit a new 52 week low of $2.26, breaking the previous low of $2.35 from earlier this month. Adamis Pharmaceuticals Corp swung 11.95% between low and high. In addition to the stock finishing lower, the trading volumes were only 0.00% of normal which could be an indication of investor uncertainty.

ADMP was outperformed by the rest of the Healthcare sector which went up 0.31%.

Adamis Pharmaceuticals Corp Info

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company’s specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of albuterol (APC-2000) for the treatment of bronchospasms; fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, ophthalmic preparations, topical compounds for pain, and men’s and women’s health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.

All amounts in USD unless otherwise indicated

ADMP daily update
ADMP daily update

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.